Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamiparib - BeOne Medicines

Next Previous
Drug Profile

Pamiparib - BeOne Medicines

Alternative Names: BeiGene-290; BGB-290; BGB-290- BeOne Medicines; PARPi - BeOne Medicines; PARTRUVIX

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeOne Medicines; Myriad Genetics
  • Class Antineoplastics; Aza compounds; Fluorinated hydrocarbons; Ketones; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Cancer
  • Phase II Gastric cancer; HER2 negative breast cancer
  • Phase I/II Glioblastoma; Glioma; Solid tumours
  • Suspended Prostate cancer

Most Recent Events

  • 05 Apr 2024 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase 0/II trial in Glioblastoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 28 Feb 2024 No recent reports of development identified for phase-0 development in Glioblastoma(Neoadjuvant therapy) in USA (PO, Capsule)
  • 08 Feb 2024 BeiGene in collaboration with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and National Cancer Institute completes a phase I/II clinical trials in Glioma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03914742)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top